CDK9 Overexpression

CI-VAR-00003186Explore in graph →CIViC 2584

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Hepatocellular Carcinoma1
CDK9 Overexpression	Dinaciclib	Predictive	D	Supports Sensitivity Response	3	submitted	EID9312 This preclinical study elucidated the potential varying efficaciousness of cyclin dependent Kinase inhibitor (CDK) dinaciclib. When forcing overexpression of differing CDKs (CDK1 and 9). Overall Hepat… (full text at CIViC) PMID 31561409 · Shao et al., 2019 · Open in CIViC	civic
Malignant Esophageal Neoplasm1
CDK9 Overexpression	Alvocidib + CAN508Combination	Predictive	D	Supports Sensitivity Response	4	submitted	EID9311 Cyclin-dependent kinase 9 (CDK9) was predominantly overexpressed in esophageal carcinoma tumor samples compared to normal esophageal cell lines. This high expression was also found in 90% of invasive …

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Neuroblastoma1
CDK9 Overexpression	Dinaciclib	Predictive	D	Supports Sensitivity Response	3	submitted	EID7012 As shown in Fig. 3a, all six NB cells showed relatively high expression levels of RNAP II, CDK2, and CDK9, suggesting that CDK2 and CDK9 may be ideal targets in NB therapy...Therefore, we hypothesize … (full text at CIViC) PMID 27378523 · Chen et al., 2016 · Open in CIViC	civic